LU-001i

• Description :

  LU-001i is a highly specific proteasome β1i (LMP2) inhibitor. LU-001i alone has no significant immunomodulatory effect, but when combined with the LMP7 inhibitor (PRN1126), it can exert anti-inflammatory and immunomodulatory effects. LU-001i can be used for the study of autoimmune diseases[1].

• CAS Number :

  [1620107-60-9]

• UNSPSC :

  12352005

• Target :

  Proteasome

• Related Pathways :

  Metabolic Enzyme/Protease

• Field of Research :

  Inflammation/Immunology

• Smiles :

  O=C([C@@H]1CC(F)(F)CN1C([C@@H](NC(CN=[N+]=[N-])=O)C)=O)N[C@@H](CCCC)C(N[C@@H](CC2CCCCC2)C([C@]3(C)OC3)=O)=O

• Molecular Formula :

  C28H43F2N7O6

• Molecular Weight :

  611.68

• References & Citations :

  [1]Basler M, et al. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Rep. 2018 Dec;19 (12) :e46512.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported